Kymera TherapeuticsKYMR
Market Cap: $2.93B
About: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Employees: 181
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
38% more call options, than puts
Call options by funds: $961K | Put options by funds: $698K
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
0.86% less ownership
Funds ownership: 110.65% [Q1] → 109.79% (-0.86%) [Q2]
3% less funds holding
Funds holding: 161 [Q1] → 156 (-5) [Q2]
16% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 31
26% less capital invested
Capital invested by funds: $2.72B [Q1] → $2.01B (-$707M) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Wolfe Research Andy Chen 67% 1-year accuracy 6 / 9 met price target | 43%upside $65 | Outperform Upgraded | 26 Aug 2024 |
Morgan Stanley James Quigley 0 / 0 met price target | 1%downside $45 | Equal-Weight Maintained | 14 Aug 2024 |
Wells Fargo Derek Archila 53% 1-year accuracy 16 / 30 met price target | 16%downside $38 | Equal-Weight Maintained | 12 Aug 2024 |
Oppenheimer Jeff Jones 75% 1-year accuracy 18 / 24 met price target | 15%upside $52 | Outperform Maintained | 10 Jul 2024 |
B. Riley Securities Kalpit Patel 38% 1-year accuracy 5 / 13 met price target | 21%downside $36 | Neutral Maintained | 9 Jul 2024 |
Financial journalist opinion
Based on 7 articles about KYMR published over the past 30 days